1
|
Herbelin A, Cayssials E, Jacomet F, Nunez NG, Basbous S, Lefevre L, Abdallah M, Piccirilli N, Lavoue V, Catros V, Piaggio E, Gombert JM, Barbarin A. Eomesodermin together with KIR/NKG2A membrane receptors and CD49d as an useful strategy to identify NK-like CD8(+) T cells with innate features in humans: focusing on cancer diseases. The Journal of Immunology 2017. [DOI: 10.4049/jimmunol.198.supp.196.2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Abstract
Among the burgeoning family of unconventional T cells, innate-like CD8(+) T cells bear a memory phenotype without having encountered a foreign antigen and can respond to innate-like IL-12+IL-18 stimulation. Although the concept of innate memory (IM) CD8(+) T cells is now well-established in mice, whether an equivalent memory NK-like T-cell population exists in humans remains under debate. We recently reported that CD8(+) T cells responding to innate-like IL-12+IL-18 stimulation and co-expressing the transcription factor Eomesodermin (Eomes) and KIR/NKG2A membrane receptors with a memory/EMRA phenotype may represent a new, functionally distinct innate T cell subset in humans.
Here, we proposed Eomes together with KIR/NKG2A and CD49d as a signature to standardize the identification of this innate CD8(+) T-cell subset in humans. Focusing on cancer diseases, we have provided new insights into the potential role of these IM CD8(+) T cells in a physiopathological context in humans. Based on empirical data obtained in cases of chronic myeloid leukemia, a myeloproliferative syndrome controlled by the immune system, and in solid tumors, we have observed both the possible contribution of IM CD8(+) T cells to cancer disease control and their susceptibility to tumor immune subversion. Finally, we have investigated the involvement of IL-4 and IL-15 in the generation of the IM CD8(+) T cell pool and its dependency on promyelocytic leukemia zinc finger (PLZF)-expressing invariant Natural Killer T (iNKT) cells.
All in all, this study significantly contributes to understanding of the physiopathological role of NK-like CD8(+) T cells in humans and raises the question of the possible involvement of an iNKT/IM CD8(+) T cell axis in cancer.
Collapse
|
2
|
Barbarin A, Cayssials E, Jacomet F, Nunez NG, Basbous S, Lefèvre L, Abdallah M, Piccirilli N, Morin B, Lavoue V, Catros V, Piaggio E, Herbelin A, Gombert JM. Phenotype of NK-Like CD8(+) T Cells with Innate Features in Humans and Their Relevance in Cancer Diseases. Front Immunol 2017; 8:316. [PMID: 28396661 PMCID: PMC5366313 DOI: 10.3389/fimmu.2017.00316] [Citation(s) in RCA: 38] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2016] [Accepted: 03/06/2017] [Indexed: 11/13/2022] Open
Abstract
Unconventional T cells are defined by their capacity to respond to signals other than the well-known complex of peptides and major histocompatibility complex proteins. Among the burgeoning family of unconventional T cells, innate-like CD8(+) T cells in the mouse were discovered in the early 2000s. This subset of CD8(+) T cells bears a memory phenotype without having encountered a foreign antigen and can respond to innate-like IL-12 + IL-18 stimulation. Although the concept of innate memory CD8(+) T cells is now well established in mice, whether an equivalent memory NK-like T-cell population exists in humans remains under debate. We recently reported that CD8(+) T cells responding to innate-like IL-12 + IL-18 stimulation and co-expressing the transcription factor Eomesodermin (Eomes) and KIR/NKG2A membrane receptors with a memory/EMRA phenotype may represent a new, functionally distinct innate T cell subset in humans. In this review, after a summary on the known innate CD8(+) T-cell features in the mouse, we propose Eomes together with KIR/NKG2A and CD49d as a signature to standardize the identification of this innate CD8(+) T-cell subset in humans. Next, we discuss IL-4 and IL-15 involvement in the generation of innate CD8(+) T cells and particularly its possible dependency on the promyelocytic leukemia zinc-finger factor expressing iNKT cells, an innate T cell subset well documented for its susceptibility to tumor immune subversion. After that, focusing on cancer diseases, we provide new insights into the potential role of these innate CD8(+) T cells in a physiopathological context in humans. Based on empirical data obtained in cases of chronic myeloid leukemia, a myeloproliferative syndrome controlled by the immune system, and in solid tumors, we observe both the possible contribution of innate CD8(+) T cells to cancer disease control and their susceptibility to tumor immune subversion. Finally, we note that during tumor progression, innate CD8(+) T lymphocytes could be controlled by immune checkpoints. This study significantly contributes to understanding of the role of NK-like CD8(+) T cells and raises the question of the possible involvement of an iNKT/innate CD8(+) T cell axis in cancer.
Collapse
Affiliation(s)
- Alice Barbarin
- INSERM 1082, Poitiers, France; CHU de Poitiers, Poitiers, France
| | - Emilie Cayssials
- INSERM 1082, Poitiers, France; CHU de Poitiers, Poitiers, France; Service d'Hématologie et d'Oncologie Biologique, CHU de Poitiers, Poitiers, France; Université de Poitiers, Poitiers, France
| | - Florence Jacomet
- INSERM 1082, Poitiers, France; CHU de Poitiers, Poitiers, France; Université de Poitiers, Poitiers, France; Service d'Immunologie et Inflammation, CHU de Poitiers, Poitiers, France
| | - Nicolas Gonzalo Nunez
- Institut Curie, PSL Research University, INSERM U932, Paris, France; SiRIC Translational Immunotherapy Team, Translational Research Department, Research Center, Institut Curie, PSL Research University, Paris, France; Centre d'Investigation Clinique Biothérapie CICBT 1428, Institut Curie, Paris, France
| | - Sara Basbous
- INSERM 1082, Poitiers, France; Université de Poitiers, Poitiers, France
| | | | - Myriam Abdallah
- INSERM 1082, Poitiers, France; CHU de Poitiers, Poitiers, France
| | | | | | - Vincent Lavoue
- INSERM U1242, Rennes, France; CHU de Rennes, Rennes, France
| | - Véronique Catros
- CHU de Rennes, Rennes, France; INSERM U991, Rennes, France; CRB Santé de Rennes, Rennes, France
| | - Eliane Piaggio
- Institut Curie, PSL Research University, INSERM U932, Paris, France; SiRIC Translational Immunotherapy Team, Translational Research Department, Research Center, Institut Curie, PSL Research University, Paris, France; Centre d'Investigation Clinique Biothérapie CICBT 1428, Institut Curie, Paris, France
| | - André Herbelin
- INSERM 1082, Poitiers, France; CHU de Poitiers, Poitiers, France; Université de Poitiers, Poitiers, France
| | - Jean-Marc Gombert
- INSERM 1082, Poitiers, France; CHU de Poitiers, Poitiers, France; Université de Poitiers, Poitiers, France; Service d'Immunologie et Inflammation, CHU de Poitiers, Poitiers, France
| |
Collapse
|
3
|
Pérol L, Lindner JM, Caudana P, Nunez NG, Baeyens A, Valle A, Sedlik C, Loirat D, Boyer O, Créange A, Cohen JL, Rogner UC, Yamanouchi J, Marchant M, Leber XC, Scharenberg M, Gagnerault MC, Mallone R, Battaglia M, Santamaria P, Hartemann A, Traggiai E, Piaggio E. Loss of immune tolerance to IL-2 in type 1 diabetes. Nat Commun 2016; 7:13027. [PMID: 27708334 PMCID: PMC5059699 DOI: 10.1038/ncomms13027] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2016] [Accepted: 08/25/2016] [Indexed: 12/28/2022] Open
Abstract
Type 1 diabetes (T1D) is characterized by a chronic, progressive autoimmune attack against pancreas-specific antigens, effecting the destruction of insulin-producing β-cells. Here we show interleukin-2 (IL-2) is a non-pancreatic autoimmune target in T1D. Anti-IL-2 autoantibodies, as well as T cells specific for a single orthologous epitope of IL-2, are present in the peripheral blood of non-obese diabetic (NOD) mice and patients with T1D. In NOD mice, the generation of anti-IL-2 autoantibodies is genetically determined and their titre increases with age and disease onset. In T1D patients, circulating IgG memory B cells specific for IL-2 or insulin are present at similar frequencies. Anti-IL-2 autoantibodies cloned from T1D patients demonstrate clonality, a high degree of somatic hypermutation and nanomolar affinities, indicating a germinal centre origin and underscoring the synergy between cognate autoreactive T and B cells leading to defective immune tolerance. Type 1 diabetes is driven by T-cell autoimmunity to pancreatic islet cells. Here the authors show that autoreactive anti-IL-2 T and B cells are present in type 1 diabetes patients, and that anti-IL-2 antibodies precede diabetes onset in mice, suggesting their potential as a diagnostic marker.
Collapse
Affiliation(s)
- Louis Pérol
- Sorbonne Universités, Pierre and Marie Curie University Paris 06, Paris 75005, France.,Centre National de la Recherche Scientifique, UMR 7211, Paris 75013, France.,Institut National de la Santé et de la Recherche Médicale (INSERM), U 959, Immunology- Immunopathology-Immunotherapy (I3), Paris 75013, France.,Institut Curie, PSL Research University, INSERM U932, F-75005 Paris, France.,SiRIC TransImm Translational Immunotherapy Team, Translational Research Department, Research Center, PSL Research University, Institut Curie, Paris F-75005, France.,Centre d'Investigation Clinique Biothérapie CICBT 1428, Institut Curie, Paris F-75005, France
| | - John M Lindner
- Novartis Institutes for Biomedical Research, Basel 4056, Switzerland
| | - Pamela Caudana
- Institut Curie, PSL Research University, INSERM U932, F-75005 Paris, France.,SiRIC TransImm Translational Immunotherapy Team, Translational Research Department, Research Center, PSL Research University, Institut Curie, Paris F-75005, France.,Centre d'Investigation Clinique Biothérapie CICBT 1428, Institut Curie, Paris F-75005, France
| | - Nicolas Gonzalo Nunez
- Institut Curie, PSL Research University, INSERM U932, F-75005 Paris, France.,SiRIC TransImm Translational Immunotherapy Team, Translational Research Department, Research Center, PSL Research University, Institut Curie, Paris F-75005, France.,Centre d'Investigation Clinique Biothérapie CICBT 1428, Institut Curie, Paris F-75005, France
| | - Audrey Baeyens
- Sorbonne Universités, Pierre and Marie Curie University Paris 06, Paris 75005, France.,Centre National de la Recherche Scientifique, UMR 7211, Paris 75013, France.,Institut National de la Santé et de la Recherche Médicale (INSERM), U 959, Immunology- Immunopathology-Immunotherapy (I3), Paris 75013, France
| | - Andrea Valle
- Diabetes Research Institute (DRI), IRCCS San Raffaele Scientific Institute, Milan 20132, Italy
| | - Christine Sedlik
- Institut Curie, PSL Research University, INSERM U932, F-75005 Paris, France.,SiRIC TransImm Translational Immunotherapy Team, Translational Research Department, Research Center, PSL Research University, Institut Curie, Paris F-75005, France.,Centre d'Investigation Clinique Biothérapie CICBT 1428, Institut Curie, Paris F-75005, France
| | - Delphine Loirat
- SiRIC TransImm Translational Immunotherapy Team, Translational Research Department, Research Center, PSL Research University, Institut Curie, Paris F-75005, France.,Centre d'Investigation Clinique Biothérapie CICBT 1428, Institut Curie, Paris F-75005, France
| | - Olivier Boyer
- INSERM, U905, Rouen 76183, France.,Normandie Univ. IRIB, Rouen 76183, France.,Rouen University Hospital, Laboratory of Immunology, Rouen 76183, France
| | - Alain Créange
- Service de Neurologie, Groupe Hospitalier Henri Mondor, AP-HP, Créteil F-94010, France.,EA 4391, Université Paris Est, Créteil F-94010, France
| | - José Laurent Cohen
- Université Paris-Est Créteil, Créteil F-94010, France.,INSERM U 955, Institut Mondor de Recherche Biomédicale (IMRB), Créteil F-94010, France.,AP-HP, Groupe Hospitalier Henri-Mondor Albert-Chenevier, CIC-BT-504, Créteil F-94010, France
| | - Ute Christine Rogner
- Institut Pasteur, CNRS URA 2578, Département Biologie du développement et cellules souches, Paris 75015, France
| | - Jun Yamanouchi
- Julia McFarlane Diabetes Research Centre and Department of Microbiology, Immunology and Infectious Diseases, Snyder Institute for Chronic Diseases, Cumming School of Medicine. University of Calgary, Calgary, Alberta, Canada T2N 4N1
| | - Martine Marchant
- Novartis Institutes for Biomedical Research, Basel 4056, Switzerland
| | | | - Meike Scharenberg
- Novartis Institutes for Biomedical Research, Basel 4056, Switzerland
| | - Marie-Claude Gagnerault
- INSERM, U1016, Cochin Institute, DeAR Lab, Paris 75014, France.,Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Service de Diabétologie, Paris 75014, France.,Paris Descartes University, Sorbonne Paris Cité, Faculté de Médecine, Paris 75270, France
| | - Roberto Mallone
- INSERM, U1016, Cochin Institute, DeAR Lab, Paris 75014, France.,Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Service de Diabétologie, Paris 75014, France.,Paris Descartes University, Sorbonne Paris Cité, Faculté de Médecine, Paris 75270, France
| | - Manuela Battaglia
- Diabetes Research Institute (DRI), IRCCS San Raffaele Scientific Institute, Milan 20132, Italy
| | - Pere Santamaria
- Julia McFarlane Diabetes Research Centre and Department of Microbiology, Immunology and Infectious Diseases, Snyder Institute for Chronic Diseases, Cumming School of Medicine. University of Calgary, Calgary, Alberta, Canada T2N 4N1.,Institut D'Investigacions Biomediques August Pi i Sunyer, Barcelona 08036, Spain
| | - Agnès Hartemann
- Department of Medicine Faculty, Université Pierre et Marie Curie-Paris 6, Paris 75005, France.,Department of Endocrinology, Nutrition and Diabetes, Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière-Charles Foix Hospital, Paris 75013, France
| | | | - Eliane Piaggio
- Sorbonne Universités, Pierre and Marie Curie University Paris 06, Paris 75005, France.,Centre National de la Recherche Scientifique, UMR 7211, Paris 75013, France.,Institut National de la Santé et de la Recherche Médicale (INSERM), U 959, Immunology- Immunopathology-Immunotherapy (I3), Paris 75013, France.,Institut Curie, PSL Research University, INSERM U932, F-75005 Paris, France.,SiRIC TransImm Translational Immunotherapy Team, Translational Research Department, Research Center, PSL Research University, Institut Curie, Paris F-75005, France.,Centre d'Investigation Clinique Biothérapie CICBT 1428, Institut Curie, Paris F-75005, France
| |
Collapse
|